VIDEO: Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies By admin / 06/04/2021
Efficacy and Safety of Ublituximab vs Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results from Two Phase 3 Studies ULTIMATE I & ULTIMATE II American Academy of Neurology By admin / 04/17/2021
A Phase 3, Randomized Trial of Ublituximab Plus Ibrutinib for Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukaemia By admin / 02/22/2021
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) By admin / 12/07/2020
Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL By admin / 12/07/2020
VIDEO: Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL By admin / 12/07/2020
VIDEO: A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) By admin / 12/07/2020
Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies By admin / 12/05/2020
VIDEO: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies By admin / 12/05/2020
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study By admin / 11/04/2020
